Aspirin discontinuation syndromes: Clinical implications of basic research studies

American Journal of Cardiovascular Drugs

Volumn 13, Issue 6, 2013, Pages 377-384

  Doutremepuich, Christian ^a   Aguejouf, Omar ^a   Desplat, Vanessa ^a   Eizayaga, Francisco X ^b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b DEPARTAMENTO DE CIENCIAS NATURALES Y ANTROPOLOGÍA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PLACEBO; SALICYLIC ACID; THROMBOCYTE ACTIVATING FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; ASPIRIN DISCONTINUATION SYNDROME; BLOOD CLOTTING; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; IN VIVO STUDY; KNOCKOUT MOUSE; LASER-INDUCED THROMBOSIS; LOW DRUG DOSE; MESENTERY BLOOD VESSEL; MICROVASCULATURE; MONOTHERAPY; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; REBOUND; SINGLE DRUG DOSE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; THROMBOSIS; WITHDRAWAL SYNDROME;

ANIMALS; ASPIRIN; BIOMEDICAL RESEARCH; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MICE, KNOCKOUT; RATS; SUBSTANCE WITHDRAWAL SYNDROME; THROMBOSIS;

EID: 84890481742     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-013-0044-1     Document Type: Article

References (36)

1. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS; COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1607-21.
2. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-17.
3. Sibon I, Orgogozo JM. Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology. 2004;62(7):1187-9.
4. Maulaz AB, Bezerra DC, Michel P, Bogousslavsky J. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol. 2005;62(8):1217-20.
5. Armstrong MJ, Schneck MJ, Biller J. Discontinuation of perioperative antiplatelet and anticoagulant therapy in stroke patients. Neurol Clin. 2006;24(4):607-30.
6. Fischer LM, Schlienger RG, Matter CM, Jick H, Meier CR. Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction. Arch Intern Med. 2004;164(22):2472-6.
7. Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol. 2005;45(3):456-9.
8. Burger W, Chemnitius JM, Kneissl GD, Rucker G. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. J Intern Med. 2005;257(5):399-414.
9. Collet JP, Montalescot G, Blanchet B, Tanguy ML, Golmard JL, Choussat R, Beygui F, Payot L, Vignolles N, Metzger JP, Thomas D. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation. 2004;110(16):2361-7.
10. Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, Krumholz HM, Rumsfeld JS. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006;166(17):1842-7.
11. Biondi-Zoccai GG, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F, Testa L, Sheiban I, Sangiorgi G. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006;27(22):2667-74.
12. Collet JP, Himbet F, Steg PG. Myocardial infarction after aspirin cessation in stable coronary artery disease patients. Int J Cardiol. 2000;76(2-3):257-8.
13. Albaladejo P, Geeraerts T, Francis F, Castier Y, Leseche G, Marty J. Aspirin withdrawal and acute lower limb ischemia. Anesth Analg. 2004;99(2):440-3.
14. Eisenberg MJ, Richard PR, Libersan D, Filion KB. Safety of short-term discontinuation antiplatelet therapy in patients with drug-eluting stents. Circulation. 2009;119(12):1634-42.
15. Fitzgerald GA. Parsing an enigma: the pharmacodynamics of aspirin resistance. Lancet. 2003;361:542-4.
16. Awtry EH, Loscalzo J. Aspirin. Circulation. 2000;101:1206-18.
17. Wu KK. Aspirin and salicylate: an old remedy with a new twist. Circulation. 2000;102:2022-3.
18. Gurfinkel EP, Altman R, Scazziota A, Heguilen R, Mautner B. Fast platelet suppression by lysine acetylsalicylate in chronic stable coronary patients. Potential clinical impact over regular aspirin for coronary syndromes. Clin Cardiol. 2000;23(9):697-700.
19. Patrignani P, Filabozi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin unhealthy subjects. J Clin Invet. 1982;69:1366-72.
20. Reilly IAG, FitGerald GA. Inhibition of thromboxane formation in vivo and ex vivo. Blood. 1987;69:180-6.
21. Hoogendijk EMG, ten Cate JW. Aspirin and platelets. Lancet. 1980;1(8159):93-4.
22. Jakubowski JA, Stamfer MJ, Vaillancourt R, Deykin D. Cumulative ant platelet effect of low-dose enteric coated aspirin. Br J Haematol. 1982;60:635-42.
23. Vesvres MH, Doutremepuich F, Lalanne MC, Doutremepuich C. Effects of aspirin on embolization in an arterial model of laser-induced thrombus formation. Haemostasis. 1993;23(1):8-12.
24. Doutremepuich C, Aguejouf O, Belon P. Effects of ultra-low-dose aspirin on embolization in a model of laser-induced thrombus formation. Semin Thromb Hemost. 1996;22(Suppl 1):67-70.
25. Aguejouf O, Eizayaga F, Desplat V, Belon P, Doutremepuich C. Prothrombotic and hemorrhagic effects of aspirin. Clin Appl Thromb Hemost. 2009;15(5):523-8.
26. Aguejouf O, Belougne-Malfatti E, Doutremepuich F, Belon P, Doutremepuich C. Thromboembolic complications several days after a single-dose administration of aspirin. Thromb Res. 1998;89(3):123-7.
27. Czevionke RL, Hoak M, Fry GL. Effect of aspirin on non thrombin-induced adherence of platelets to cultured vessel wall. J Clin Invest. 1978;62:847-56.
28. Mc Manus LM, Hanahan, DJ, Pinckard RN. Human platelet stimulation by acetyl glyceryl ether phosphorylcholine. J Clin Invest. 1981;67:903-6.
29. Doutremepuich C, Aguejouf O, Desplat V, Eizayaga FX. Paradoxical thrombotic effects of aspirin: experimental study on 1000 animals. Cardiovasc Hematol Disord Drug Targets. 2010;10(2):103-10.
30. Doutremepuich C, Aguejouf O, Eizayaga FX, Desplat V. Reverse effect of aspirin: is the pro-thrombotic effect after aspirin discontinuation mediated by cycloxygenase 2 inhibition? Pathophysiol Haemost Thromb. 2007;36(1):40-4.
31. Skill NJ, Theodorakis NG, Wang YN, Wu JM, Redmond EM, Sitzmann JV. Role of cyclooxygenase isoforms in prostacyclin biosynthesis and murine prehepatic portal hypertension. Am J Physiol Gastrointest Liver Physiol. 2008;295(5):G953-64.
32. Taubert D, Berkels R, Grosser N, Schröder H, Gründemann D, Schömig E. Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action. Br J Pharmacol. 2004;143(1):159-65.
33. Vial JH, McLeod LJ, Roberts MS. Rebound elevation in urinary thromboxane B2 and 6-keto-PGF1 alpha excretion after aspirin withdrawal. Adv Prostaglandin Thromboxane Leukot Res. 1991;21A:157-60.
34. Mousa SA, Forsythe MS, Bozarth JM, Reilly TM. Effect of single oral dose of aspirin on human platelet function and plasma plasminogen activator inhibitor-1. Cardiology. 1993;83:367-73.
35. Fatah K, Beving H, Albâge A, Ivert T, Blombäck M. Acetylsalicylic acid may protect the patient by increasing fibrin gel porosity. Is withdrawing of treatment harmful to the patient? Eur Heart J. 1996;17:1362-6.
36. Lordkipanidzé M, Diodati JG, Pharand C. Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: a look at the clinical and pharmacological evidence. Pharmacol Ther. 2009;123:178-86.